article

1. Screening Strategies for Identification of Transthyretin Amyloid Cardiomyopathy..  JACC. Heart failure.  -. 2026
2. Exercise training for the prevention and treatment of cardiometabolic disease..  Current opinion in cardiology.  2026
3. A multi-layered approach to elucidate mechanisms of physical function in response to rehabilitation in heart failure with preserved ejection fraction..  medRxiv : the preprint server for health sciences.  2026
4. Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes..  JACC. Heart failure.  14:-. 2025
5. Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy..  Scientific reports.  15:-. 2025
6. Cardiovascular Aging and Exercise: Implications for Heart Failure Prevention and Management..  Circulation research.  137:205-230. 2025
7. Aerobic, resistance, and specialized exercise training in heart failure with preserved ejection fraction: A state-of-the-art review..  Heart failure reviews.  30:1015-1034. 2025
8. Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: The PARAGLIDE-HF Trial..  American heart journal.  158-167. 2025
9. Functional Sarcopenia and Physical Rehabilitation Response in Older Adults Hospitalized for Acute Heart Failure: A Secondary Analysis of the REHAB-HF Trial..  Circulation. Heart failure.  18:-. 2025
10. Framework of the strengths and challenges of clinically integrated trials: An expert panel report..  American heart journal.  62-73. 2024
11. Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction..  ESC heart failure.  11:2813-2824. 2024
12. Effect of Exercise Training on Peak Aerobic Power After Heart Transplantation: A Brief Review..  The Canadian journal of cardiology.  39:S368-S374. 2023
13. Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF..  American heart journal.  22-30. 2023
14. Advancing the evidence for diuretic therapy for heart failure: implications of the ADVOR and TRANSFORM-HF trials..  European heart journal. Cardiovascular pharmacotherapy.  9:299-300. 2023
15. New Paradigms to Address Long-Term Exercise Adherence, An Achilles Heel of Lifestyle Interventions..  Circulation.  147:1565-1567. 2023
16. Echocardiographic Features Beyond Ejection Fraction and Associated Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction..  Circulation. Heart failure.  16:-. 2023
17. Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy..  medRxiv : the preprint server for health sciences.  2023
18. Quality of Care and Outcomes Among Patients Hospitalized for Heart Failure in Rural vs Urban US Hospitals: The Get With The Guidelines-Heart Failure Registry..  JAMA cardiology.  8:376-385. 2023
19. Phenomapping in heart failure with preserved ejection fraction - insights, limitations, and future directions..  Cardiovascular research.  118:3403-3415. 2023
20. Continuous Monitoring of Heart Rate Variability and Clinical Outcomes in Patients with Implantable Cardioverter Defibrillators..  Current problems in cardiology.  48:-. 2022
21. The evolving landscape of pulmonary arterial hypertension clinical trials..  Lancet (London, England).  400:1884-1898. 2022
22. A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative..  Contemporary clinical trials.  -. 2022
23. Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020..  The American journal of cardiology.  129-136. 2022
24. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction..  Cardiology clinics.  40:473-489. 2022
25. Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF..  JACC. Heart failure.  10:918-927. 2022
26. Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction..  Journal of cardiac failure.  28:1652-1660. 2022
27. An evaluation of torsemide in patients with heart failure and renal disease..  Expert review of cardiovascular therapy.  20:5-11. 2022
28. Circulating fibrocyte levels correlate with infarct size in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention..  American heart journal plus : cardiology research and practice.  2021
29. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT..  ESC heart failure.  8:842-848. 2021
30. Author's Response to Imamura and Colleagues..  Journal of cardiac failure.  25:-. 2019
31. Comparative Analysis of Established Risk Scores and Novel Hemodynamic Metrics in Predicting Right Ventricular Failure in Left Ventricular Assist Device Patients..  Journal of cardiac failure.  25:620-628. 2019
32. Recurrent Myocarditis Imitating ST Segment Elevation Myocardial Infarction..  Journal of medical cases.  9:239-242. 2018
33. Trends and Predictors of Participation in Cardiac Rehabilitation Following Acute Myocardial Infarction: Data From the Behavioral Risk Factor Surveillance System..  Journal of the American Heart Association.  7. 2017
34. Patient Engagement Following Acute Myocardial Infarction and Its Influence on Outcomes..  The American journal of cardiology.  120:1467-1471. 2017
35. High-throughput and combinatorial technologies for tissue engineering applications..  Tissue engineering. Part B, Reviews.  15:225-39. 2009